Standard BioTools to sell its Microfluidics business to ARCHIMED, close in about 30 days

Standard BioTools agreed to sell its Microfluidics business to healthcare-focused investor ARCHIMED. Closing is targeted in about 30 days, subject to customary closing conditions, with Microfluidics operations remaining at Standard BioTools until the deal closes.